198 related articles for article (PubMed ID: 19448397)
1. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.
Brody JR; Costantino CL; Berger AC; Sato T; Lisanti MP; Yeo CJ; Emmons RV; Witkiewicz AK
Cell Cycle; 2009 Jun; 8(12):1930-4. PubMed ID: 19448397
[TBL] [Abstract][Full Text] [Related]
2. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
[TBL] [Abstract][Full Text] [Related]
3. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
Speeckaert R; Vermaelen K; van Geel N; Autier P; Lambert J; Haspeslagh M; van Gele M; Thielemans K; Neyns B; Roche N; Verbeke N; Deron P; Speeckaert M; Brochez L
Eur J Cancer; 2012 Sep; 48(13):2004-11. PubMed ID: 22033321
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction.
Lee JH; Chen Y; Chan JL; Qian YW; Goydos JS
Cancer Immunol Immunother; 2011 May; 60(5):685-92. PubMed ID: 21327637
[TBL] [Abstract][Full Text] [Related]
6. Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.
Gide TN; Allanson BM; Menzies AM; Ferguson PM; Madore J; Saw RPM; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Histopathology; 2019 May; 74(6):817-828. PubMed ID: 30589949
[TBL] [Abstract][Full Text] [Related]
7. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer.
Nakamura T; Shima T; Saeki A; Hidaka T; Nakashima A; Takikawa O; Saito S
Cancer Sci; 2007 Jun; 98(6):874-81. PubMed ID: 17433037
[TBL] [Abstract][Full Text] [Related]
8. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
Chevolet I; Speeckaert R; Haspeslagh M; Neyns B; Krüse V; Schreuer M; Van Gele M; Van Geel N; Brochez L
Br J Dermatol; 2014 Nov; 171(5):987-95. PubMed ID: 24814041
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free Survival.
Rubel F; Kern JS; Technau-Hafsi K; Uhrich S; Thoma K; Häcker G; von Bubnoff N; Meiss F; von Bubnoff D
J Invest Dermatol; 2018 Mar; 138(3):679-687. PubMed ID: 29054599
[TBL] [Abstract][Full Text] [Related]
10. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis.
Yu J; Sun J; Wang SE; Li H; Cao S; Cong Y; Liu J; Ren X
Clin Dev Immunol; 2011; 2011():469135. PubMed ID: 22110525
[TBL] [Abstract][Full Text] [Related]
11. FoxP3 and IDO in Canine Melanocytic Tumors.
Porcellato I; Brachelente C; De Paolis L; Menchetti L; Silvestri S; Sforna M; Vichi G; Iussich S; Mechelli L
Vet Pathol; 2019 Mar; 56(2):189-199. PubMed ID: 30381008
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β and interferon γ in metastatic lymph nodes in malignant melanoma.
Pelak MJ; Śnietura M; Lange D; Nikiel B; Pecka KM
Pol J Pathol; 2015 Dec; 66(4):376-82. PubMed ID: 27003769
[TBL] [Abstract][Full Text] [Related]
13. FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients.
Ryan M; Crow J; Kahmke R; Fisher SR; Su Z; Lee WT
Am J Otolaryngol; 2014; 35(6):689-94. PubMed ID: 25212103
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer.
Mansfield AS; Heikkila PS; Vaara AT; von Smitten KA; Vakkila JM; Leidenius MH
BMC Cancer; 2009 Jul; 9():231. PubMed ID: 19604349
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood.
Ikemoto T; Shimada M; Komatsu M; Yamada S; Saito Y; Mori H; Morine Y; Imura S; Bando Y; Utsunomiya T
Pancreas; 2013 Jan; 42(1):130-4. PubMed ID: 22722263
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase and regulatory t cells in intestinal mucosa in children with inflammatory bowel disease.
Sznurkowska K; Żawrocki A; Sznurkowski J; Iżycka-Świeszewska E; Landowski P; Szlagatys-Sidorkiewicz A; Plata-Nazar K; Kamińska B
J Biol Regul Homeost Agents; 2017; 31(1):125-131. PubMed ID: 28337881
[TBL] [Abstract][Full Text] [Related]
17. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma.
Ryu HS; Park YS; Park HJ; Chung YR; Yom CK; Ahn SH; Park YJ; Park SH; Park SY
Thyroid; 2014 Aug; 24(8):1232-40. PubMed ID: 24742251
[TBL] [Abstract][Full Text] [Related]
18. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
19. IDO recruits Tregs in melanoma.
Prendergast GC; Metz R; Muller AJ
Cell Cycle; 2009 Jun; 8(12):1818-9. PubMed ID: 19471123
[No Abstract] [Full Text] [Related]
20. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.
Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K
Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
